Q-omics provides the consensus-scored TAF9 profile across patient tissues and cancer cell-line models. TAF9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TAF9 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TAF9 RNA expression shows 18,876 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where TAF9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF9 survival associations across molecular data types. TAF9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF9 RNA expression–survival associations across cancer types. High TAF9 expression shows unfavorable associations in KICH, ACC, HNSC, LIHC and UVM, but favorable associations in READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TAF9 RNA expression.
This table summarizes TAF9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TAF9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF9 shows higher tumor expression in HNSC, KIRC, LIHC, COAD, LUAD and UCEC. The HNSC box plot shows higher TAF9 RNA expression in tumor versus normal tissue (log2 FC = +0.711, t-test p < 0.001).
This table shows molecular features associated with TAF9 in patient tissues and cancer cell lines. In patient samples, TAF9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
